Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma – single center experience
, and | Apr 08, 2019
About this article
Article Category: Original Article/Praca Oryginalna
Published Online: Apr 08, 2019
Page range: 39 - 44
Received: Feb 13, 2019
Accepted: Mar 06, 2019
DOI: https://doi.org/10.34763/devperiodmed.20192301.3944
© 2019 Anna Raciborska, Katarzyna Bilska, Carlos Rodriguez-Galindo, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Patient and treatment characteristics at time of original diagnosis (n=15).
| Gender | N% |
|---|---|
| Male | 8 (53,3%) |
| Female | 7 (46,7%) |
| Median age in years | 12.4 |
| Primary tumor location | |
| Extremity | 9 (60%) |
| Axis | 6 (40%) |
| Metastasis at initial diagnosis | 11 |
| Site of metastases at diagnosis | |
| Lungs | 9 (81,8%) |
| Lungs + Bones | 2 (18,2%) |
| Local treatment at diagnosis | |
| Surgery only | 6 (40%) |
| RTX only | 3 (20%) |
| Both | 6 (40%) |
| Neoadjuvant chemotherapy | |
| VIDE regimen | 14 (93,3%) |
| CAV/ETIF regimen | 1 (6,7%) |
| Bone marrow transplant in 1 CR | 7 (47%) |
| Follow-up | |
| Relapse | 11 (73,3%) |
| Progression on primary therapy | 1 (6,7%) |
| Median TTR in months | 9.9 |
Patient characteristics, response to trofosfamide, and outcome.
| Patient nb. | Stage at dlagn. | Patient characteristic according to the treatment | Intention of trofosfamide maintenance therapy | Status of disease before trofosfamide | Nb. of courses | Best response | Toxicity (grade 2-4) | Reason for stopping therapy | Treatment after trofosfamlde | Status (last follow up In years) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Met. | 1st line | radical | CR | 8 | CR | renal dysfunction | renal toxicity | - | NED (2.0) |
| 2 | Met. | 1st line | radical | CR | 4 | CR | renal dysfunction | renal toxicity | - | NED (1.4) |
| 3 | Met. | progression on the 1st line | radical | CR | 10 | CR | renal dysfunction | renal toxicity | - | NED (4.3) |
| 4 | Loc. | relapse | radical | CR | 12 | CR | none | end of treatment | - | NED (6.3) |
| 5 | Loc. | relapse | palliative | PD | 2 | PD | none | death | - | DOD (7.7) |
| 6 | Loc. | relapse | Palliative | PD | 2 | PD | none | death | - | DOD (9.9) |
| 7 | Met. | relapse | radical | CR | 6 | CR | none | still in treatment | - | NED (3.3) |
| 8 | Loc. | relapse | palliative | PD | 2 | PD | none | progression | VP | DOD (5.7) |
| 9 | Met. | 1st line | radical | CR | 1 | CR | leucopenia | marrow toxicity | - | NED (3.2) |
| 10 | Met. | relapse | radical | CR | 13 | CR | none | end of treatment | - | NED (7.6) |
| 11 | Met. | relapse | palliative | PD | 5 | PD | none | death | - | DOD (3.5) |
| 12 | Met. | relapse | radical | CR | 8 | CR | none | end of treatment | - | NED (5.2) |
| 13 | Met. | relapse | palliative | SD | 8 | PD | none | progression | VN/CTX, T | AWD (3.9) |
| 14 | Met. | relapse | radical | CR | 3 | PD | none | progression | TC. HD-IFO | AWD (1.5) |
| 15 | Met. | relapse | radical | CR | 11 | CR | none | end of treatment | - | NED (3.9) |